SMPD4
protein-codingsphingomyelin phosphodiesterase 4
Gene summary
The protein encoded by this gene is a sphingomyelinase that catalyzes the hydrolysis of membrane sphingomyelin to form phosphorylcholine and ceramide. This gene is activated by DNA damage, cellular stress, and tumor necrosis factor, but it is downregulated by wild-type p53. The encoded protein localizes to the endoplasmic reticulum and Golgi network. [provided by RefSeq, Mar 2017]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~31.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0032838
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0032838
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0032838
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0032838
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Craniofacial; Musculoskeletal; Neurologic
Intervention: Cardiovascular
Rationale: Among other features, individuals have been described with cardiac anomalies, including structural defects as well as cardiomyopathy, and prompt diagnosis may allow early management of these issues and sequelae
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to SMPD4 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_017951.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 32 | 2 | 35 | ||
| missense | 3 | 162 | 7 | 172 | ||
| nonsense | 1 | 5 | 3 | 9 | ||
| start loss | 0 | |||||
| frameshift | 4 | 13 | 2 | 19 | ||
| splice donor/acceptor (+/-2bp) | 4 | 4 | 5 | 13 | ||
| Total | 9 | 25 | 173 | 39 | 2 | 248 |
Highest pathogenic variant AF is 0.000040896957
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_060421.3 | 19 | MANE Select | |
| Ensembl | ENSP00000506463.1 | 19 | MANE Select | |
| RefSeq | NP_001164554.1 | 17 | Standard | |
| RefSeq | NP_060221.2 | 19 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Sphingolipid metabolism - Homo sapiens (human)
- Metabolism of lipids
- sphingomyelin metabolism/ceramide salvage
- Metabolism
- Glycosphingolipid metabolism
Biological Process
- sphingomyelin catabolic process
- glycosphingolipid metabolic process
- glycerophospholipid catabolic process
- ceramide biosynthetic process
- cellular response to tumor necrosis factor
Molecular Function
- sphingomyelin phosphodiesterase activity
- metal ion binding
- sphingomyelin phosphodiesterase D activity
Cellular Component
- Golgi membrane
- endoplasmic reticulum
- endoplasmic reticulum membrane
- Golgi apparatus
- trans-Golgi network
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000409031
- Coding exons
- 20
- Length
- 31343
- Individuals with no LoFs
- 125679
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 69
- Defined
- 125748
- p
- 0.000274
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.857 | 474 | 530 | 0.895 | 0.0000326 | 5591 |
| Missense (PolyPhen) | 142 | 155.74 | 0.9118 | 1496 | ||
| Synonymous | -1.42 | 256 | 229 | 1.12 | 0.0000151 | 1743 |
| Loss of Function | 1.43 | 35 | 45.4 | 0.771 | 0.00000225 | 485 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000064 | 0.000062 | rare |
| Latino/Admixed American | 0.00029 | 0.00029 | rare |
| Ashkenazi Jewish | 0.00021 | 0.00020 | rare |
| East Asian | 0.00023 | 0.00022 | rare |
| Finnish | 0.000046 | 0.000046 | rare |
| European (Non-Finnish) | 0.00034 | 0.00033 | rare |
| South Asian | 0.00030 | 0.00029 | rare |
| Other | 0.00067 | 0.00065 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Catalyzes the hydrolysis of membrane sphingomyelin to form phosphorylcholine and ceramide (PubMed:16517606). May sensitize cells to DNA damage-induced apoptosis (PubMed:18505924). {ECO:0000269|PubMed:16517606, ECO:0000269|PubMed:18505924}.;
Recessive Scores
- pRec
- 0.102
Intolerance Scores
- LoFtool
- 0.0439
- RVIS EVS
- -1.39
- RVIS percentile EVS
- 4.31
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.519
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |